TheEdgeResearch
Home / Stocks / TBPH

Theravance Biopharma Inc (TBPH)

NASDAQ Healthcare Biotechnology
$17.03 ▲ +0.00%
Market Cap
$884.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.17
52-Wk Range
—
CEO
Rick E. Winningham
Country
US
Currency
USD

Theravance Biopharma Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $17.03, up 0.00% on the session, giving a market capitalisation of $884.2M. On trailing twelve-month figures it carries a trailing P/E of 16.01, a net margin of 51.6%. Its beta of 0.17 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
16.01
Price / Sales
8.48
Price / Book
3.04
EV / EBITDA
10.24
Gross margin
89.4%
Operating margin
4.5%
Net margin
51.6%
Return on equity
—
Debt / equity
0.13
Current ratio
13.54
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
90
IPO date
2014-05-16
Headquarters
South San Francisco, CA, US
About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Comparable companies

Theravance Biopharma Inc is most often compared with the following Healthcare names:

GOSSMNKD
More research on TBPH
TBPH technical analysis TBPH TheEdge Score Compare against peers
Open full interactive analysis & DCF →